WO2002046413A3 - Molecules for disease detection and treatment - Google Patents

Molecules for disease detection and treatment Download PDF

Info

Publication number
WO2002046413A3
WO2002046413A3 PCT/US2001/046874 US0146874W WO0246413A3 WO 2002046413 A3 WO2002046413 A3 WO 2002046413A3 US 0146874 W US0146874 W US 0146874W WO 0246413 A3 WO0246413 A3 WO 0246413A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mddt
disease detection
molecules
provides
Prior art date
Application number
PCT/US2001/046874
Other languages
French (fr)
Other versions
WO2002046413A2 (en
Inventor
Jennifer L Jackson
Mariah R Baughn
Henry Yue
Kimberly J Gietzen
Y Tom Tang
Kavitha Thangavelu
Preeti G Lal
Yuming Xu
Vicki S Elliott
Dyung Aina M Lu
Monique G Yao
Yan Lu
April J A Hafalia
Jayalaxmi Ramkumar
Original Assignee
Incyte Genomics Inc
Jennifer L Jackson
Mariah R Baughn
Henry Yue
Kimberly J Gietzen
Y Tom Tang
Kavitha Thangavelu
Preeti G Lal
Yuming Xu
Vicki S Elliott
Dyung Aina M Lu
Monique G Yao
Yan Lu
April J A Hafalia
Jayalaxmi Ramkumar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Jennifer L Jackson, Mariah R Baughn, Henry Yue, Kimberly J Gietzen, Y Tom Tang, Kavitha Thangavelu, Preeti G Lal, Yuming Xu, Vicki S Elliott, Dyung Aina M Lu, Monique G Yao, Yan Lu, April J A Hafalia, Jayalaxmi Ramkumar filed Critical Incyte Genomics Inc
Priority to AU2002239543A priority Critical patent/AU2002239543A1/en
Priority to US10/433,544 priority patent/US20040053396A1/en
Publication of WO2002046413A2 publication Critical patent/WO2002046413A2/en
Publication of WO2002046413A3 publication Critical patent/WO2002046413A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides full-length human molecules for disease detection and treatment (MDDT) and polynucleotides which identify and encode MDDT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of MDDT.
PCT/US2001/046874 2000-12-07 2001-12-04 Molecules for disease detection and treatment WO2002046413A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002239543A AU2002239543A1 (en) 2000-12-07 2001-12-04 Molecules for disease detection and treatment
US10/433,544 US20040053396A1 (en) 2001-12-04 2001-12-04 Molecules for disease detection and treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25179100P 2000-12-07 2000-12-07
US60/251,791 2000-12-07

Publications (2)

Publication Number Publication Date
WO2002046413A2 WO2002046413A2 (en) 2002-06-13
WO2002046413A3 true WO2002046413A3 (en) 2003-09-04

Family

ID=22953419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046874 WO2002046413A2 (en) 2000-12-07 2001-12-04 Molecules for disease detection and treatment

Country Status (2)

Country Link
AU (1) AU2002239543A1 (en)
WO (1) WO2002046413A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282696A4 (en) * 2000-03-13 2005-02-09 Curagen Corp Ifi206, a novel interferon-induced polypeptide, and nucleic acids encoding the same
US20040152092A1 (en) * 2001-05-11 2004-08-05 Alex Smolyar Regulation of human phosphatidic acid phosphatase type 2c-like protein
US20070142288A1 (en) * 2005-12-20 2007-06-21 Pappachan Kolattukudy Isolated MCPIP and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
WO2001057188A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 February 2000 (2000-02-01), XP002223626, retrieved from EBI Database accession no. AW337474 *
JOHNSTONE RICKY W ET AL: "The human interferon-inducible protein, IFI 16, is a repressor of transcription.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 27, 3 July 1998 (1998-07-03), pages 17172 - 17177, XP002223625, ISSN: 0021-9258 *
TRAPANI J A ET AL: "A NOVEL GENE CONSTITUTIVELY EXPRESSED IN HUMAN LYMPHOID CELLS IS INDUCIBLE WITH INTERFERON-GAMMA IN MYELOID CELLS", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 36, no. 6, 1 September 1992 (1992-09-01), pages 369 - 376, XP000605287, ISSN: 0093-7711 *
TRAPANI J A ET AL: "GENOMIC ORGANIZATION OF IFI16, AN INTERFERON-INDUCIBLE GENE WHOSE EXPRESSION IS ASSOCIATED WITH HUMAN MYELOIS CELL DIFFERENTIATION: CORRELATION OF PREDICTED PROTEIN DOMAINS WITH EXON ORGANIZATION", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 6, 1 October 1994 (1994-10-01), pages 415 - 424, XP000576202, ISSN: 0093-7711 *

Also Published As

Publication number Publication date
WO2002046413A2 (en) 2002-06-13
AU2002239543A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO2002046383A3 (en) Protein modification and maintenance molecules
WO2002063005A3 (en) Lipid-associated molecules
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2002002603A3 (en) Protein modification and maintenance molecules
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2002026950A3 (en) Transferases
WO2001096546A3 (en) Protein phosphatases
WO2001032888A3 (en) Human transferase molecules
WO2001098471A3 (en) Human phosphodiesterases
WO2002060942A3 (en) Protein modification and maintenance molecules
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2003063688A3 (en) Protein modification and maintenance molecules
WO2004009797A3 (en) Protein modification and maintenance molecules
WO2004053068A3 (en) Protein modification and maintenance molecules
WO2003052049A3 (en) Molecules for disease detection and treatment
WO2003031595A3 (en) Molecules for disease detection and treatment
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2003031939A3 (en) Protein modification and maintenance molecules
WO2001055358A3 (en) Phosphodiesterases
WO2002046413A3 (en) Molecules for disease detection and treatment
WO2002078420A3 (en) Molecules for disease detection and treatment
WO2003046152A3 (en) Molecules for disease detection and treatment
WO2002042330A3 (en) Cystoskeleton-associated proteins
WO2003100016A3 (en) Protein modification and maintenance molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10433544

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP